Wei Zhan; Xiaoyin Bai; Hong Yang; Jiaming Qian

doi:10.5217/ir.2024.00021

Articles

Page Path: HOME > Intest Res > Ahead-of print articles > Article

Original Article Perianal fistulizing lesions of Crohn’s disease are associated with long-term behavior and its transition: a Chinese cohort study: Wei Zhan, Xiaoyin Bai, Hong Yang^,, Jiaming Qian^,; DOI: https://doi.org/10.5217/ir.2024.00021
Published online: July 15, 2024

Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China

Correspondence to Hong Yang, Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No.1 Shuaifuyuan, Wangfujing Street, Beijing 100730, China. Tel: +86-10-69155014, Fax: +86-10-69155014, E-mail: yangh@pumch.cn

Co-Correspondence to Jiaming Qian, Department of Gastroenterology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, No.1 Shuaifuyuan, Wangfujing Street, Beijing, 100730, China. Tel: +86-10-69155019, Fax: +86-10-65124875, E-mail: qianjm@pumch.cn

• Received: February 1, 2024 • Revised: April 3, 2024 • Accepted: April 22, 2024

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

700 Views
81 Download

Full Article

Download PDF

Abstract
INTRODUCTION
METHODS
RESULTS
DISCUSSION
NOTES
Supplementary Material
REFERENCES

Abstract

Background/Aims
Crohn’s disease (CD) has a progressive nature and commonly perianal involvement. The aim of this study is to assess the prevalence, surgical treatment, and outcome of perianal fistulizing CD with associated risk factors in a large Chinese cohort.
Methods
Hospitalized patients diagnosed with CD in our center were consecutively enrolled between January 2000 and December 2018. Transition of disease behavior was classified according to the presence or absence of penetrating behavior (B3 in the Montreal classification) at diagnosis and at a median follow-up of 102 months.
Results
A total of 504 patients were included, of whom 207 (41.1%) were classified as B3 and 348 (69.0%) as L2/3 at follow-up. Transition of behavior to B3 was observed in 86 patients (17.1%). The incidence of perianal fistulizing lesions was 10.9% at 10 years with a final prevalence of 27.0% (n = 136) at the end of follow-up. Multivariate Cox regression identified independent risks of perianal fistulizing lesions for persistent B3 (hazard ratio, 4.72; 95% confidence interval, 1.91–11.66) and behavior transition of progressed to B3 (hazard ratio, 9.90; 95% confidence interval, 4.60–21.33). Perianal surgical treatments were performed in 104 patients (20.6%). Thirty-six cases (7.1%) were refractory, and it is independently associated with behavior of persistent B3 (P=0.011).
Conclusions
Perianal fistulizing lesions occurred frequently in Chinese CD patients. Its incidence and refractory outcome were closely associated with the penetrating CD behavior. An additional risk of perianal fistulizing lesions was indicated for CD patients with behavior of progressing to B3, suggesting further attention.
Keywords: Crohn disease; Rectal diseases; Intestinal fistula; Disease progression

INTRODUCTION

Crohn’s disease (CD) is a chronic inflammatory bowel disease that widely affects the gastrointestinal tract with a progressive disease course for its following transition in location and behavior [1]. Perianal involvement is one of the most common manifestations in CD with different types including ulceration, fistula or abscess, stricture according to the Cardiff classification [2], while perianal fistulizing CD (fistulas/abscesses) represents a common but aggressive phenotype with severely impaired quality of life [3-5]. Management of perianal fistulizing CD encompasses medical and surgical interventions. Local surgical interventions such as drainage seton or fistulotomy with the assistance of symptomatic antibiotic and immunomodulator/biologic application are preferred options according to different fistula anatomy and response [5].

Estimates of the incidence of perianal fistulizing CD in U.S. and European cohorts with 5-year follow-up ranged from 11.6% to 17% [6]. Prolonged follow-up has also revealed that the incidence cumulates, for example, from 15.8% to 29.5% at 10 years after diagnosis to over 28.3% at 20 years [6-8]. In contrast, it is believed that perianal CD is more common in East Asia with a prevalence of up to 58.8% in newly diagnosed CD [9,10], and a recent nationwide study from Korea presented a 40.0% incidence of perianal fistulizing CD at 5 years after diagnosis [11]. This significance remained in South Asian CD patients compared with Caucasians in the United States [12], suggesting differences in inherited susceptibility and clinical manifestations. In addition, the incidence of CD in Asia, and particularly in China, is increasing along with the resulting disease burden during dramatic changes in socioeconomic status and lifestyle [9,13].

Current knowledge about the risk of perianal lesions in CD awaits improvement. Numerous factors have been reported to associate with the risk of perianal lesions by several cohorts, including male sex, younger age at CD diagnosis, different disease manifestations, and the luminal behavior of CD like colonic disease location and internal penetrating behavior [6]; however, the power of these associations was limited by small number of studies with heterogeneity. Furthermore, the detailed impact of the luminal behavior of CD, with its natural tendency toward transition, remains unknown. Research into the transitional nature of CD may be the key to improving its management and prognosis [14,15]. Previously the association of behavior progression with the risk of CD-related surgery was demonstrated in a large-scale Chinese CD cohort [16]. To go one step further, we evaluated the incidence and clinical characteristics of perianal fistulizing CD and tested its association with luminal behavior progression in this long-term follow-up Chinese population.

METHODS

1. Subject Recruitment and Follow-up

Hospitalized CD patients were consecutively enrolled from January 2000 to December 2018. Details of the definitions and methodologies used to recruit and follow-up subjects in this cohort have been published previously [16] and would be described below. CD was diagnosed by gastroenterologists based on clinical, imaging, endoscopic, and histologic evidence according to the contemporary Chinese and European consensus [17,18]. Follow-up data were collected from medical records if the patients revisited as expected. To reduce recall bias, patients were asked to revisit if the disease remained active or if they presented with CD-related complications (including perianal lesions; all definition details were provided in “Data Collection and Variable Definition”), otherwise, the relevant information was allowed to be obtained by contacting the patients or their relatives by telephone or e-mail biennially or triennially. The most recent follow-up was completed in December 2020. Patients who refused or were lost to followup were excluded; only patients with an unchanged primary diagnosis of CD and a minimum follow-up of 2 years were included in the present study (Supplementary Fig. 1).

2. Data Collection and Variable Definition

Information on demographics (age at diagnosis, sex) and exposure to environmental risk (smoking status) was collected from patients. Smoking status was defined as current (self-reported regular and ongoing smoking; all these subjects reported duration of more than 1 year), former (previously regular smoking but currently quit), and never. Clinical disease activity was determined using the Harvey-Bradshaw Index, with a score of < 5 as remission, 5–7 as mild activity, 8–16 as moderate activity, and ≥ 16 as severe activity [19]. The Montreal classification was applied as the criteria for coding of age at diagnosis (A1, ≤ 16 years; A2, 17–40 years; and A3, > 40 years), disease location (L1, small bowel; L2, colon; L3, small bowel and colon; and L4, upper gastrointestinal tract), and behavior (B1, nonstricturing/nonpenetrating); B2, stricturing; and B3, penetrating; perianal disease was classified independently) [20]. Disease location and behavior were reviewed at the end of follow-up, with disease behavior or location transition additionally classified according to different B3 or L2/3, respectively, at diagnosis and follow-up. Endoscopic activity of CD in patients without bowel surgery was determined based on evaluation and cutoffs of Simple Endoscopic Score for Crohn’s Disease [21] at the enrollment, with cutoffs applied to define activity groups as the result: inactive 0–2; mild 3–6; moderate 7–15; and severe > 16. Perianal fistulizing lesions (fistula, abscess) were diagnosed based on physical examination with confirmation by ultrasound, magnetic resonance imaging and/or endoscopy at CD diagnosis or follow-up according to the Cardiff classification [2]. Surgical treatment of drainage setons, fistulectomy and fistulotomy was documented. Refractory perianal lesion was defined as perianal symptoms exacerbating at any time after related effective therapy. In addition, extraintestinal manifestations [17] at diagnosis, medical therapy (systematic corticosteroids, immunomodulators, and biologics), severe CD-related complications (massive gastrointestinal bleeding, intestinal obstruction or perforation), and CD-related surgery (i.e., the gastrointestinal tract resection or enterostomy) during the follow-up were recorded and included in the statistical analysis.

3. Statistical Analysis

Descriptive analyses were presented as median and interquartile range (IQR) for continuous variables and proportions for categorical variables. The Pearson chi-square test or the Fisher exact test was used to compare categorical variables when appropriate. Because our focus was on the transitional behavior of the disease, the Kaplan-Meier survival curve with log-rank test was applied in the univariate analysis for incidence during follow-up only. Additionally, a multivariate Cox regression model of incidence with proportional hazard assumption was assessed and summarized as hazard ratios (HRs) with 95% confidence intervals (CIs). Other multivariate analyses for perianal characteristics were conducted in logistic regression model and presented as odds ratios (ORs) with 95% CI. All multivariable models used stepwise forward selection of potentially more significant factors with a filter of likelihood ratio 0.10 to prevent overfitting. All statistical significance was defined as P<0.05. Statistical analyses were performed using SPSS 26.0 (IBM Corp., Armonk, NY, USA).

4. Ethical Statements

The study protocol was approved by the Institutional Review Board of Peking Union Medical College Hospital (I-23PJ1310), and written informed consent was obtained from all participants. The study is conducted in accordance with the Declaration of Helsinki.

RESULTS

1. Characteristic of CD and Perianal Fistulizing Lesions

A total of 504 CD patients with a median age of 30.0 years (IQR, 20.9–42.3 years) were included in this study (Supplementary Fig. 1), of whom 349 (69.2%) were male. Perianal fistulizing lesions occurred in 136 (27.0%) patients after a median follow-up of 102 months (IQR, 68–142 months), and data for detailed demographic and clinical characteristics were summarized with perianal fistulizing lesions (Table 1). The Montreal age classification of A3 consisted of 144 patients (28.6%). Among 321 (63.7%) patients with any colonic involvement (L2/L3) at diagnosis, the disease location of isolated colon (L2) and ileum-colon (L3) were 132 (26.2%) and 189 (37.5%), respectively. Penetrating behavior (B3) was present in 121 (24.0%) patients at diagnosis. The majority of disease activity at diagnosis was classified as moderate in 230 patients (45.6%), while 88 patients (17.5%) were classified as severe. At follow-up, a trend toward CD progression was indicated as the number of patients with colonic involvement increased to 348 (69.0%), including 256 for L3 (50.8%). Penetrating behaviors also increased to 207 of B3 (41.1%). Medical therapy was commonly applied as corticosteroid for 380 (75.4%), immunomodulator for 280 (55.6%) and biologic for 105 (28.3%) patients. Extraintestinal manifestations were reported in approximately half of the patients (n = 249, 49.4%), severe complications of CD were reported in 286 patients (56.7%), and CD-related surgery was performed in 211 patients (48.9%).

Characteristics of perianal lesions were summarized in Table 2. The number of patients with perianal fistulizing lesions at diagnosis was 95 (18.8%) and notably, an additional 41 patients (8.1%) developed perianal fistulizing lesions during the follow-up period. Among all 136 (27.0%) patients with perianal fistulizing lesions, there were 100 (19.8%) cases of fistula and 81 (16.1%) cases of perianal abscess. A total of 104 (76.5%) cases received perianal surgical treatment, including 17 (12.5%) cases of drainage seton only, 67 (49.3%) cases of fistulotomy, and 37 (27.2%) cases of fistulectomy. Refractory perianal lesions were present in 26.5% of the total perianal fistulizing lesions (36/136) and 29.8% of the cases that received perianal surgical treatment (31/104).

2. Factors Associated with Perianal Fistulizing Lesions

Differences and potential associations between perianal fistulizing lesions and CD characteristics were evaluated in univariate analyses (Table 1). Perianal fistulizing lesions were significantly associated with sex (P<0.001), the Montreal classification of age (P<0.001), location at diagnosis (P=0.001) and follow-up (P<0.001), behavior at diagnosis and follow-up (both P<0.001), disease activity (P=0.010), extraintestinal manifestation (P=0.049), biological therapy (P<0.001), severe complication of obstruction (P=0.012), and CD-related surgery (P<0.001). Additionally, all medical and surgical treatments prior to perianal fistulizing lesions were summarized and compared: 24.3% of cases (33/136, P<0.001) used corticosteroids, 14.0% (19/117, P < 0.001) used immunomodulators, 7.4% (10/136, P = 0.028) used biologics, and 5.1% (7/136, P<0.001) underwent surgery. Bi-level analysis for perianal fistulizing lesions showed significant increases in the percentages of location classification of L2/L3 (77.2% vs. 58.7% at diagnosis, P<0.001; 83.8% vs. 63.6% at follow-up, P<0.001), behavior classification of B3 (37.5% vs. 19.0% at diagnosis, P<0.001; 63.2% vs. 32.9% at follow-up, P<0.001), and disease activity of severe (26.5% vs. 14.1%, P=0.001). Perianal fistulizing lesions were significantly associated with a decrease in age classification of A3 (14.0% vs. 34.0%, P<0.001). There was no significant difference of perianal fistulizing lesions between L2 and L3 at diagnosis (P=0.244) or follow-up (P=0.208).

Endoscopic activity was assessed and compared in 266 patients without CD-related surgery, 95 of whom presented with perianal fistulizing lesions. No statistical difference of activity was identified between groups with or without perianal fistulizing lesions (P=0.316) (Supplementary Table 1).

3. Transition of CD and Its Association with Perianal Fistulizing Lesions

Transition of CD occurred in 120 (23.8%) for behavior (B transition) and 87 (17.3%) for location (L transition). The median time to transition was 26.5 months (IQR, 9.0–68.3 months) for behavior and 34.5 months (IQR, 12.4–76.6 months) for location after diagnosis. Of 231 patients initially classified as B1, only 136 patients (58.9%) remained at the end of follow-up, while 34 (14.7%) and 61 (26.4%) of them progressed to B2 and B3, respectively. In addition, 25 out of 152 patients (16.4%) progressed from B2 to B3. Thus, all CD behavior with its transitional trend could be classified into 3 categories: non-B3 (297, 58.9%), progressed to B3 (86, 17.1%), and persistent B3 (121, 24.0%). A similar classification could be applied to CD location. As perianal lesions were proven to be associated with colonic involvement, location trends could be classified as non-L2/3 (144, 28.6%), progressed to L3 (39, 7.7%), and persistent L2/3 (321, 63.7%). The rate of perianal fistulizing lesions was significantly different when compared within both transition groups (both P<0.001) (Fig. 1).

Kaplan-Meier curves were plotted for 41 perianal lesions after diagnosis. The median time to onset was 36 months (IQR, 10.0–83.5 months). The time-to-event plot showed that the cumulative percentage of perianal fistulizing CD was 2.7% at 1 year, 7.2% at 5 years, 10.9% at 10 years, and 16.6% at 20 years after diagnosis (Fig. 2). Plotting the incidence according to different CD behavior transitions revealed a significant difference for B3 at the end of follow-up (log-rank P<0.001), but not at diagnosis (log-rank P=0.472) (Fig. 3A and B). Furthermore, pairwise log-rank tests indicated significant differences for each of the 2 categories of B3 trends (P<0.001 for non-B3 with progressed to B3, P=0.012 for non-B3 with persistent B3, and P=0.036 for persistent B3 with progressed to B3) (Fig. 3C). Besides, there were significant associations of incidence for both of CD location at diagnosis and follow-up (log-rank P=0.005 and 0.013, respectively) (Supplementary Fig. 2A and B); however, pairwise log-rank tests showed significance only for non-L2/3 with persistent L2/3 (P=0.004) but not for others (Supplementary Fig. 2C).

4. Multivariate Regression Analysis for Perianal Fistulizing Lesions

A multivariate Cox regression model was constructed for the incidence of perianal fistulizing lesions using forward selection of possible significant factors discussed above, including variables describing transition of CD location and behavior. The final model identified significantly associated risk factors for each B3 trend (HR, 9.90; 95% CI, 4.60–21.33; P<0.001 for progressed to B3 and HR, 4.72; 95% CI, 1.91–11.67; P=0.001 for persistent B3), and extraintestinal manifestation (HR, 2.03; 95% CI, 1.04–3.93; P=0.037) as well. Risk was also suggested by intensified disease activity compared to remission, but pairwise differences were not statistically significant (HR 2.11, P=0.506 for mild; HR 6.29, P=0.073 for moderate; HR 5.59, P=0.104 for severe). Receiving CD-related surgery (HR, 0.08; 95% CI, 0.03–0.20; P<0.001) and immunomodulator therapy (HR, 0.42; 95%, 0.21–0.84; P=0.014) were associated with a lower risk of perianal fistulizing lesions after diagnosis (Table 3).

Multivariate analyses were also performed to determine factors associated with perianal treatment. Since surgical treatment was common for most perianal fistulizing CD in our cohort, only second-line surgical treatment of fistulotomy and fistulectomy was included in the analysis. Logistic regression of perianal fistulotomy/fistulectomy found a significant association with B3 trends of progressed to B3 (OR, 0.16; 95% CI, 0.05–0.54; P=0.003) and disease activity of mild at diagnosis (OR, 8.96; 95% CI, 1.20–66.72; P=0.032) (Table 4). For refractory perianal fistulizing lesions, multivariate regression model identified the only significant association with B3 trends of persistent B3 (OR, 3.91; 95% CI, 1.36–11.23; P=0.011), predicting a worse prognosis for perianal CD (Table 5).

DISCUSSION

In this long-term CD cohort, the association of perianal fistulizing lesions with disease behavior and its transition was analyzed. There are 3 important findings as follows. First, we found a prevalence of perianal fistulizing lesions of 27.0% at the end of follow-up in this long-term Chinese CD cohort. A large proportion of the perianal fistulizing cases occurred before the diagnosis of CD, and the new lesions comprised 30.1% of the perianal cases with a 10-year incidence of 10.9%. Second, there was a significant impact of behavior transition to penetrating behavior (B3) on the higher incidence of perianal fistulizing CD. Finally, statistics of surgical treatment and refractoriness of perianal fistulizing lesions were presented, indicating that the refractory lesion was independently associated with persistent penetrating CD luminal behavior.

The prevalence and the percentage of new lesions in our study were in parallel with the report of the HKIBDR cohort from territory-wide Hong Kong (28.8% and 27.6%, respectively), which has a similar ethnic setting and also an overwhelming prevalence of perianal abscess and fistula among all types of perianal lesions [22]. In comparison to a high prevalence of 58.8% from an earlier cohort from Guangdong, China, their patients were recruited from the most developed region of China with a relatively small sample size [10]. In another recent cohort study from Japan, 48.2% prevalence of total perianal lesions was reported, with a higher proportion of perianal fistula (28.8%) but less abscess (14.7%) [23]. Through genetic differences from country to country may also contribute to our relatively low prevalence among East Asia, this pattern of prevalence was in line with the growth of socioeconomic status, and therefore vigilance should be maintained in monitoring CD perianal lesions in China.

We analyzed the impact of CD location and behavior on perianal fistulizing lesions. Multiple previous studies reported that both types of colonic involvement including isolated colon (L2) [24,25] or extended to ileocolonic (L3) [11,23,24] could be associated with perianal fistulizing lesions, suggesting a major behavioral difference between colonic and ileal CD. However, most of the associations were univariate, and they were not reliable for each of the L2/L3 across the studies. Correspondingly, in our cohort, we described the association for both L2 and L3 with perianal fistulizing lesions, which failed the test for multivariate significance. Instead, the association with penetrating behavior (B3) was consistent between our result and that of other cohorts [11,22,24,26,27]. Further pathophysiologic studies are required to explain this prevalence, as luminal and perianal fistulizing behavior may not share a similar mechanism [27,28].

We signified the prevalence of perianal fistulizing lesions not only for B3 at follow-up but also the disease behavior transition towards B3. Even though the behavior of persistent B3 significantly increased the cumulative percentage of perianal fistulizing lesions, the behavior transition from B1/2 to B3 provided an additional significant increment on the Kaplan-Meier plot. This effect remained to be significant with a considerable HR of 6.47 (95% CI, 3.04–13.8) in multivariate Cox regression. It is widely accepted that CD has a progressive nature from the initial inflammation to subsequent intestinal stricture and/or penetration. Our previous study of this cohort has detailed the portrait of the CD behavioral transition with correlated factors [16]. Few studies have linked the progression of CD behavior to the manifestation of perianal disease activity at this time. In a French cohort study aiming at the behavioral evolution of CD, a remarkable 70% of 1,199 CD patients developed a penetrating behavior 20 years after diagnosis, while perianal fistulizing lesions accounted for more than 50% of them [26]. Another survival analysis from a New Zealand cohort proposed that perianal disease was a predictor of change in CD behavior, with a significant HR of 1 [62.29]. Our result was the first to conclude a solid perianal lesion risk for disease behavior transition towards B3, signifying it as a marker of uncontrolled CD pathogenesis with relapsing courses and wide involvement.

CD-related surgery was observed to independently reduce the risk of perianal fistulizing lesions in our multivariate Cox regression analysis. Surgery for luminal disease is considered a major event for CD patients and is usually the endpoint of many CD research studies, as the decision for surgery is mainly based on severe disease activity with likely complications; however, the discussion on postoperative presentation of perianal CD in real-world cohorts has been very limited due to high patient heterogeneity and decreasing sample size with improving CD management over time. Surgery attenuates CD manifestation and assists in inducing long-lasting remission by alternating the inflammatory response via diversion of fecal stream and excision of the affected bowel with high penetrability for microbiota [30,31]. An early study in 1,981 reported spontaneous healing of perianal lesions after resection and restoration of continuity [32]. The result from our cohort supported the protective effect of bowel surgery in perianal lesions, but further recruitment and follow-up of CD-related surgery cases would help to demonstrate the detailed effect of surgery.

Specific inflammatory bowel disease medical therapy with immunomodulators and biologics has been recommended in practice guidelines for the treatment of perianal fistulizing lesions [5,33]. Currently, there was low-quality evidence supporting the efficacy of immunomodulator by trials with limited sample size and sparse data in meta-analyses [5,34]; in contrast, more reliable evidence for the efficacy of infliximab in the induction and maintenance of perianal fistulizing CD was concluded by specific randomized controlled trials [35,36], although evidence was still not supportive for other biologics [37]. Our Cox regression model indicated a lower risk of perianal fistulizing lesions in patients receiving immunomodulators but not in those receiving biologics. The clinical application of biologics for the treatment of moderate to severe CD in China could be traced back to 2006 for infliximab as the dominant option for almost a decade before the emergence of adalimumab and other options, which was reflected in our cohort. However, primary non-response and secondary loss of response to anti-TNFα were occasional [38]; meanwhile, patients may discontinue biologics or take non-standard therapy due to poor compliance or limited personal income, as biologics were relatively expensive in early China. Another Danish nationwide real-world cohort reported a similar risk of perianal fistula development with biologic exposure, suggesting limited long-term disease-modifying capabilities of biologics [39]. Combining these observations, the detailed real-world effect of immunomodulators and biologics in perianal CD could be further explored in randomized controlled settings with expanded sample size, specified treatment regimens, and endpoints.

Perianal surgery was eventually performed one or more times in the majority of patients with perianal fistulizing in our cohort. The type of perianal surgical treatment is determined by specialists with reference to the manifestation [5,40]; therefore, fistulotomy and fistulectomy were selected for subgroup analysis in our case because they were second-line options with local involvement of greater extent. However, perianal surgery could be delayed in many instances, according to the specialists, due to active inflammation and especially proctitis, in order to achieve better healing. Patients were usually referred for surgical treatment after optimization of disease activity with medical therapy, which also introduced selection bias [41]. Furthermore, there is currently no well-established guideline for the diagnosis and surgical treatment of for perianal CD, and patients may undergo perianal surgery prior to CD diagnosis. All of these factors pose challenges for the evaluation of perianal surgery in this cohort study.

Meanwhile, refractory perianal lesions could be considered as a proxy for the severity of perianal CD, as it is in parallel with loss of response and impaired patient quality of life. Our multivariate analysis demonstrated the significant association for the behavior of persistent B3 but not progressed to B3. Studies tracking CD recurrence and repeated surgery have identified penetrating disease behavior as an important independent risk factor with a reported HR of up to 6.98 [42,43], but currently none have reached significance for outcome of perianal management between different studies. A multicenter Swedish cohort reviewed 119 patients with a final healing rate of 52% and stated that the risk of perianal recurrence was associated with longer disease duration, proctitis, and different surgical procedures [41]. Another multicenter study in Korea with a postoperative recurrence rate of 42% in 51 patients concluded that the only significant risk factor was escalation of medical therapy [44]. Combined with the fact that the current activity of CD cannot be reliably predicted by previous behavior [26], the duration of penetrating luminal behavior may be the key factor of perianal influence. It may be an indication that active management of the luminal activity and active monitoring of behavior transition may improve the prognosis of perianal lesions. Our cohort previously reported a relatively longer interval from diagnosis to behavior progression [16], therefore further follow-up for patients after transition may provide more explanation by analyzing the duration of behavioral influence.

There were limitations to our study as well. This is a single-center study. The sample size of perianal CD was limited, and the studied population may differ from the general Chinese CD patients nationwide. Only inpatients of this top referral medical center were enrolled, which introduced selection bias toward a higher percentage of moderate to severe CD patients. Data of CD endoscopic activity was only identified in a portion of patients without CD-related surgery. Currently, there was no general consensus about Endoscopic Score for Crohn’s Disease cutoffs, and endoscopic review was not available.

Our work was the first to summarize long-term follow-up data on perianal fistulizing CD and its association with luminal behavior and transition from a hospitalized Chinese cohort. These findings may shed light on the transitional nature of CD and mark the high-risk luminal behavior patients for more intensive follow-up and management to achieve a better quality of life in real-world clinical practice. Future research may focus on continuous data collection of CD patients with penetrating behavior transition and different treatment to improve the understanding of the pathogenesis and prognosis.

NOTES

Funding Source

This work was supported by the National Key R&D Program of China (2023YFC2507300), National High-Level Hospital Clinical Research Funding (2022-PUMCH-B-022, 2022-PUMCHC- 018, 2022-PUMCH-A-074, 2022-PUMCH-A-179), the Capital Health Research and Development of Special Foundation (2022-2-4014), CAMS Innovation Fund for Medical Sciences (2022-I2M-C&T-B-011), National Natural Science Foundation of China (81970495), National Key Clinical Specialty Construction Project (ZK108000), and Peking Union Medical College Teaching Reform in Undergraduate Education (2023zlgl008).

Conflict of Interest

Qian J is an editorial board member of the journal but was not involved in the peer reviewer selection, evaluation, or decision process of this article. No other potential conflicts of interest relevant to this article were reported.

Data Availability Statement

Not applicable.

Author Contributions

Conceptualization: Zhan W, Bai X, Yang H, Qian J. Data curation: Zhan W, Bai X, Yang H. Formal analysis: Zhan W. Funding acquisition: Yang H, Qian J. Investigation: Zhan W. Methodology; Project administration; Resources: Zhan W, Bai X, Yang H, Qian J. Software: Zhan W. Supervision: Bai X, Yang H, Qian J. Validation: Zhan W, Bai X, Yang H, Qian J. Visualization: Zhan W, Bai X. Writing - original draft: Zhan W. Writing - review & editing: Zhan W, Bai X, Yang H, Qian J. Approval of final manuscript: all authors.

Supplementary Material

Supplementary materials are available at the Intestinal Research website (https://www.irjournal.org).

Supplementary Table 1.

Difference in Endoscopic Activity of the Cohort with Perianal Fistulizing Lesions

ir-2024-00021-Supplementary-Table-1.pdf

Supplementary Fig. 1.

Flowchart of the protocol for this cohort study. CD, Crohn’s disease; PUMCH, Peking Union Medical College Hospital.

ir-2024-00021-Supplementary-Fig-1.pdf

Supplementary Fig. 2.

Comparison of cumulative percentage of perianal fistulizing lesions after diagnosis with different Crohn’s disease (CD) location. (A) Comparison at diagnosis. (B) Comparison at follow-up. (C) Comparison according to different transition trends of CD location. Classification of CD location was divided as L2 (isolated colon), L3 (ileum-colon), and L1/4 (small bowel or upper gastrointestinal tract) according to the Montreal classification.20 Pairwise log-rank tests for each of the 2 categories of location trends only reveal significant different for non-L2/3 (colon not involved) with persistent L2/3 (P=0.004 for non-L2/3 with persistent L2/3; P=0.164 for non-L2/3 with progressed to L3, and P=0.498 for progressed to L3 with persistent L2/3).

ir-2024-00021-Supplementary-Fig-2.pdf

Fig. 1.

Alluvial plot of perianal fistulizing lesions with transitional nature of Crohn’s disease (CD). (A) Transition trends of CD behavior. (B) Transition trends of CD location. Transition trends of CD were presented as the flows connecting CD behavior/location from diagnosis to end of follow-up. The flow was colored differently if perianal fistulizing lesions occurred at any time from baseline to the end of followup course (perianal fistulizing lesions=yes). The Montreal classification is as follows: behavior classification (B1, unstructured, non-invasive; B2, structured; B3, infiltrating) and location classification (L1, ileum; L2, colon; L3, ileocolic; L4, isolated upper disease).

Fig. 2.

Cumulative percentage of perianal fistulizing lesions after diagnosis of Crohn’s disease (CD). The cumulative percentage of developing perianal fistulizing lesion was 2.7% at 1 year, 7.2% at 5 years, 10.9% at 10 years, and 16.6% at 20 years after diagnosis of CD.

Fig. 3.

Comparison of cumulative percentage of perianal fistulizing lesions after diagnosis with different Crohn’s disease (CD) behavior. (A) Comparison at diagnosis. (B) Comparison at follow-up. (C) Comparison according to different transition trends of CD behavior. Classification of CD behavior was categorized as B3 (penetrating) or non-B3 (nonstricturing/nonpenetrating or stricturing) according to the Montreal classification [20]. Note that pairwise log-rank tests for each of the 2 categories of B3 trends indicates significant differences (P<0.001 for non-B3 with progressed to B3, P=0.012 for non-B3 with persistent B3, and P=0.036 for persistent B3 with progressed to B3).

Table 1.

Clinical and Demographical Characteristics of the Cohort Categorized by Perianal Fistulizing Lesions

Characteristic	Perianal lesions, No. (%)	No perianal lesion, No. (%)	P-value
Sex			< 0.001
Male	110 (80.9)	239 (64.9)
Female	26 (19.1)	129 (35.1)
Smoking history			0.740
Never	107 (78.7)	287 (78.0)
Former	16 (11.8)	38 (10.3)
Ongoing	13 (9.6)	43 (11.7)
A classification^a			< 0.001
A1	19 (14.0)	28 (7.6)
A2	98 (72.1)	215 (58.4)
A3	19 (14.0)	125 (34.0)
L classification at diagnosis^a			0.001
L1	26 (19.1)	128 (34.8)
L2	48 (35.3)	84 (22.8)
L3	57 (41.9)	132 (35.9)
L4	5 (3.7)	24 (6.5)
L classification at follow-up^a			< 0.001
L1	11 (8.1)	103 (28.0)
L2	35 (25.7)	57 (15.5)
L3	79 (58.1)	177 (48.1)
L4	11 (8.1)	31 (8.4)
B classification at diagnosis^a			< 0.001
B1	55 (40.4)	176 (47.8)
B2	30 (22.1)	122 (33.2)
B3	51 (37.5)	70 (19.0)
B classification at follow-up^a			< 0.001
B1	24 (17.6)	112 (30.4)
B2	26 (19.1)	135 (36.7)
B3	86 (63.2)	121 (32.9)
Disease activity at diagnosis^b			0.010
Remission	17 (12.5)	59 (16.0)
Mild	30 (22.1)	80 (21.7)
Moderate	53 (39.0)	177 (48.1)
Severe	36 (26.5)	52 (14.1)
Overall extraintestinal manifestation	77 (56.6)	172 (46.7)	0.049
Overall medical therapy
Corticosteroid	110 (80.9)	270 (73.4)	0.082
Immunomodulator	77 (56.6)	203 (55.2)	0.771
Biologic	51 (37.5)	54 (14.7)	< 0.001
Overall severe complications
Obstruction	30 (22.1)	124 (33.7)	0.012
Perforation	46 (33.8)	105 (28.5)	0.250
Massive gastrointestinal bleeding	15 (11.0)	47 (12.8)	0.597
Overall Crohn’s disease-related surgery	36 (26.5)	175 (47.6)	< 0.001

Patients were categorized by Crohn’s disease-related perianal fistulizing lesions at follow-up.

^a Subgroups were categorized according to the Montreal classification: age classification (A1, ≤16 yr; A2, 17-40 yr; A3, >40 yr); location classification (L1, ileal; L2, colonic; L3, ileocolonic; L4, isolated upper disease), and behavior classification (B1, non-structuring, non-penetrating; B2, structuring; B3, penetrating). [20]

^b Subgroups were categorized according to the Harvey-Bradshaw Index. [19]

Table 2.

Characteristics of Crohn’s Disease Perianal Fistulizing Lesions

Characteristic	No. of patient (%)
Perianal fistulizing lesions at diagnosis	95 (18.8)
Fistula	68 (13.5)
Abscess	61 (12.1)
Perianal fistulizing lesions at follow-up	136 (27.0)
Fistula	100 (19.8)
Abscess	81 (16.1)
Perianal surgical treatment	104 (20.6)
Drainage seton	17 (3.4)
Fistulotomy	67 (13.3)
Fistulectomy	37 (7.3)
Refractory perianal fistulizing lesions	36 (7.1)

Table 3.

Multivariate Cox Regression Model of Perianal Fistulizing Lesions after Diagnosis

Variable	Hazard ratio (95% CI)	P-value
B3 trends^a		< 0.001
Non-B3	(Ref.)
Progressed to B3	9.90 (4.60–21.33)	< 0.001
Initial B3	4.72 (1.91–11.66)	0.001
CD-related surgery before perianal fistulizing lesions	0.08 (0.03–0.20)	< 0.001
Immunomodulator therapy before perianal fistulizing lesions	0.42 (0.21–0.84)	0.014
Disease activity at diagnosis		0.024
Remission	(Ref.)
Mild	2.11 (0.23–19.19)	0.506
Moderate	6.29 (0.84–47.14)	0.073
Severe	5.59 (0.70–44.47)	0.104
Extraintestinal manifestation	2.03 (1.04–3.93)	0.037

^a B3 refers to penetrating behavior according to the Montreal classification. [20]

CI, confidence interval; Ref., reference level; CD, Crohn’s disease.

Table 4.

Multivariate Logistic Regression Model of Fistulotomy/Fistulectomy

Variable	Odds ratio (95% CI)	P-value
B3 trends^a		0.002
Non-B3	(Ref.)
Progressed to B3	0.16 (0.05–0.54)	0.003
Persistent B3	1.13 (0.41–3.13)	0.817
Disease activity at diagnosis		0.005
Remission	(Ref.)
Mild	8.96 (1.20–66.72)	0.032
Moderate	0.47 (0.12–1.78)	0.266
Severe	1.17 (0.26–5.18)	0.840
L classification at follow-up^b		0.935
L1	(Ref.)
L2	0.84 (0.16–4.58)	0.842
L3	1.16 (0.24–5.65)	0.853
L4^c	-	-

^a B3 refers to penetrating behavior according to the Montreal classification: location classification (L1, ileal; L2, colonic; L3, ileocolonic; L4, isolated upper disease). [20]

^b Subgroups were categorized according to the Montreal classification. [20]

^c Estimation of odds ratio for L4 at follow-up deviated because all subjects (n=11) received fistulotomy/fistulectomy.

CI, confidence interval; Ref., reference level.

Table 5.

Multivariate Logistic Regression Model of Refractory Perianal Fistulizing Lesions

Variable	Odds ratio (95% CI)	P-value
B3 trends^a		0.008
Non-B3	(Ref.)
Progressed to B3	0.91 (0.25–3.26)	0.882
Persistent B3	3.91 (1.36–11.23)	0.011
L classification at follow-up^b		0.061
L1	(Ref.)
L2	0.29 (0.05–1.67)	0.166
L3	0.69 (0.15–3.26)	0.641
L4	2.67 (0.37–19.47)	0.333
Crohn’s disease-related surgery	0.38 (0.13–1.09)	0.072

^a B3 refers to penetrating behavior according to the Montreal classification. [20]

^b Subgroups were categorized according to the Montreal classification: location classification (L1, ileal; L2, colonic; L3, ileocolonic; L4, isolated upper disease). [20]

CI, confidence interval; Ref., reference level.

REFERENCES

1. Burisch J, Kiudelis G, Kupcinskas L, et al. Natural disease course of Crohn’s disease during the first 5 years after diagnosis in a European population-based inception cohort: an Epi-IBD study. Gut 2019;68:423–433.PubMed
2. Hughes LE. Clinical classification of perianal Crohn’s disease. Dis Colon Rectum 1992;35:928–932.Article PubMed
3. Mahadev S, Young JM, Selby W, Solomon MJ. Quality of life in perianal Crohn’s disease: what do patients consider important? Dis Colon Rectum 2011;54:579–585.Article PubMed
4. Kasparek MS, Glatzle J, Temeltcheva T, Mueller MH, Koenigsrainer A, Kreis ME. Long-term quality of life in patients with Crohn’s disease and perianal fistulas: influence of fecal diversion. Dis Colon Rectum 2007;50:2067–2074.Article PubMed
5. Panés J, Rimola J. Perianal fistulizing Crohn’s disease: pathogenesis, diagnosis and therapy. Nat Rev Gastroenterol Hepatol 2017;14:652–664.Article PubMed PDF
6. Tsai L, McCurdy JD, Ma C, Jairath V, Singh S. Epidemiology and natural history of perianal Crohn’s disease: a systematic review and meta-analysis of population-based cohorts. Inflamm Bowel Dis 2022;28:1477–1484.Article PubMed PMC PDF
7. Schwartz DA, Loftus EV, Tremaine WJ, et al. The natural history of fistulizing Crohn’s disease in Olmsted County, Minnesota. Gastroenterology 2002;122:875–880.Article PubMed
8. Eglinton TW, Barclay ML, Gearry RB, Frizelle FA. The spectrum of perianal Crohn’s disease in a population-based cohort. Dis Colon Rectum 2012;55:773–777.Article PubMed
9. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res 2016;14:111–119.Article PubMed PMC
10. Zeng Z, Zhu Z, Yang Y, et al. Incidence and clinical characteristics of inflammatory bowel disease in a developed region of Guangdong Province, China: a prospective population-based study. J Gastroenterol Hepatol 2013;28:1148–1153.PubMed
11. Song EM, Lee HS, Kim YJ, et al. Incidence and outcomes of perianal disease in an Asian population with Crohn’s disease: a nationwide population-based study. Dig Dis Sci 2020;65:1189–1196.Article PubMed PDF
12. Jangi S, Ruan A, Korzenik J, de Silva P. South Asian patients with inflammatory bowel disease in the United States demonstrate more fistulizing and perianal Crohn phenotype. Inflamm Bowel Dis 2020;26:1933–1942.Article PubMed PDF
13. Kaplan GG, Ng SC. Globalisation of inflammatory bowel disease: perspectives from the evolution of inflammatory bowel disease in the UK and China. Lancet Gastroenterol Hepatol 2016;1:307–316.Article PubMed
14. Kennedy NA, Jones GR, Plevris N, Patenden R, Arnott ID, Lees CW. Association between level of fecal calprotectin and progression of Crohn’s disease. Clin Gastroenterol Hepatol 2019;17:2269–2276.Article PubMed PMC
15. Plevris N, Fulforth J, Lyons M, et al. Normalization of fecal calprotectin within 12 months of diagnosis is associated with reduced risk of disease progression in patients with Crohn’s disease. Clin Gastroenterol Hepatol 2021;19:1835–1844.Article PubMed
16. Bai X, Zhang H, Ruan G, et al. Long-term disease behavior and surgical intervention analysis in hospitalized patients with Crohn’s disease in China: a retrospective cohort study. Inflamm Bowel Dis 2022;28(Suppl 2): S35–S41.Article PubMed PDF
17. Inflammatory Bowel Disease Group; Chinese Society of Gastroenterology; Chinese Medical Association. Chinese consensus on diagnosis and treatment in inflammatory bowel disease (2018, Beijing). J Dig Dis 2021;22:298–317.Article PubMed PDF
18. Gomollón F, Dignass A, Annese V, et al. 3rd European evidencebased consensus on the diagnosis and management of Crohn’s disease 2016: part 1. Diagnosis and medical management. J Crohns Colitis 2017;11:3–25.Article PubMed
19. Best WR. Predicting the Crohn’s disease activity index from the Harvey-Bradshaw Index. Inflamm Bowel Dis 2006;12:304–310.Article PubMed
20. Satsangi J, Silverberg MS, Vermeire S, Colombel JF. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut 2006;55:749–753.Article PubMed PMC
21. Daperno M, D’Haens G, Van Assche G, et al. Development and validation of a new, simplified endoscopic activity score for Crohn’s disease: the SES-CD. Gastrointest Endosc 2004;60:505–512.Article PubMed
22. Mak WY, Mak OS, Lee CK, et al. Significant medical and surgical morbidity in perianal Crohn’s disease: results from a territory-wide study. J Crohns Colitis 2018;12:1392–1398.Article PubMed
23. Yamamoto T, Nakase H, Watanabe K, et al. Diagnosis and clinical features of perianal lesions in newly diagnosed Crohn’s disease: subgroup analysis from inception cohort registry study of patients with Crohn’s disease (iCREST-CD). J Crohns Colitis 2023;17:1193–1206.Article PubMed PMC PDF
24. Göttgens KW, Jeuring SF, Sturkenboom R, et al. Time trends in the epidemiology and outcome of perianal fistulizing Crohn’s disease in a population-based cohort. Eur J Gastroenterol Hepatol 2017;29:595–601.Article PubMed
25. Wils P, Leroyer A, Fumery M, Fernandez-Nistal A, Gower-Rousseau C, Pariente B. Fistulizing perianal lesions in a French population with Crohn’s disease. Dig Liver Dis 2021;53:661–665.Article PubMed
26. Cosnes J, Cattan S, Blain A, et al. Long-term evolution of disease behavior of Crohn’s disease. Inflamm Bowel Dis 2002;8:244–250.Article PubMed
27. Tang LY, Rawsthorne P, Bernstein CN. Are perineal and luminal fistulas associated in Crohn’s disease? A population-based study. Clin Gastroenterol Hepatol 2006;4:1130–1134.Article PubMed
28. Sachar DB, Bodian CA, Goldstein ES, et al. Is perianal Crohn’s disease associated with intestinal fistulization? Am J Gastroenterol 2005;100:1547–1549.Article PubMed
29. Tarrant KM, Barclay ML, Frampton CM, Gearry RB. Perianal disease predicts changes in Crohn’s disease phenotype-results of a population-based study of inflammatory bowel disease phenotype. Am J Gastroenterol 2008;103:3082–3093.Article PubMed
30. Penner RM, Madsen KL, Fedorak RN. Postoperative Crohn’s disease. Inflamm Bowel Dis 2005;11:765–777.Article PubMed
31. Bernstein CN, Loftus EV Jr, Ng SC, Lakatos PL, Moum B, Epidemiology and Natural History Task Force of the International Organization for the Study of Inflammatory Bowel Disease (IOIBD). Hospitalisations and surgery in Crohn’s disease. Gut 2012;61:622–629.Article PubMed
32. Heuman R, Bolin T, Sjödahl R, Tagesson C. The incidence and course of perianal complications and arthralgia after intestinal resection with restoration of continuity for Crohn’s disease. Br J Surg 1981;68:528–530.Article PubMed PDF
33. Sandborn WJ, Fazio VW, Feagan BG, Hanauer SB; American Gastroenterological Association Clinical Practice Committee. AGA technical review on perianal Crohn’s disease. Gastroenterology 2003;125:1508–1530.Article PubMed
34. Lee MJ, Parker CE, Taylor SR, et al. Efficacy of medical therapies for fistulizing Crohn’s disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2018;16:1879–1892.Article PubMed
35. Present DH, Rutgeerts P, Targan S, et al. Infliximab for the treatment of fistulas in patients with Crohn’s disease. N Engl J Med 1999;340:1398–1405.Article PubMed
36. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn’s disease. N Engl J Med 2004;350:876–885.Article PubMed
37. Shehab M, Alrashed F, Heron V, Restellini S, Bessissow T. Comparative efficacy of biologic therapies for inducing response and remission in fistulizing Crohn’s disease: systematic review and network meta-analysis of randomized controlled trials. Inflamm Bowel Dis 2023;29:367–375.Article PubMed PDF
38. Qiu Y, Chen BL, Mao R, et al. Systematic review with meta-analysis: loss of response and requirement of anti-TNFα dose intensification in Crohn’s disease. J Gastroenterol 2017;52:535–554.Article PubMed PDF
39. Wewer MD, Zhao M, Nordholm-Carstensen A, Weimers P, Seidelin JB, Burisch J. The incidence and disease course of perianal Crohn’s disease: a Danish nationwide cohort study, 1997-2015. J Crohns Colitis 2021;15:5–13.Article PubMed PDF
40. Sica GS, Di Carlo S, Tema G, et al. Treatment of peri-anal fistula in Crohn’s disease. World J Gastroenterol 2014;20:13205–13210.Article PubMed PMC
41. Graf W, Andersson M, Åkerlund JE, Börjesson L, Swedish Organization for Studies of Inflammatory Bowel Disease. Longterm outcome after surgery for Crohn’s anal fistula. Colorectal Dis 2016;18:80–85.Article PubMed
42. Kusaka J, Shiga H, Kuroha M, et al. Risk factors associated with postoperative recurrence and repeat surgery in Japanese patients with Crohn’s disease. Int J Colorectal Dis 2017;32:1407–1413.Article PubMed PDF
43. Buisson A, Chevaux JB, Allen PB, Bommelaer G, Peyrin-Biroulet L. Review article: the natural history of postoperative Crohn’s disease recurrence. Aliment Pharmacol Ther 2012;35:625–633.Article PubMed
44. Nam K, Jung WB, Lee SB, Soh JS, Yang SS, Jung SW. Predictors of reoperation for perianal fistula in Crohn’s disease. J Dig Dis 2021;22:334–341.Article PubMed PDF

Figure & Data

REFERENCES

Citations

Citations to this article as recorded by

PubReader
ePub Link

Cite

CITE: export Copy Download Format; Close

Download Citation

Download a citation file in RIS format that can be imported by all major citation management software, including EndNote, ProCite, RefWorks, and Reference Manager.

Format:

RIS — For EndNote, ProCite, RefWorks, and most other reference management software
BibTeX — For JabRef, BibDesk, and other BibTeX-specific software

Include:

Citation for the content below
Citation and abstract for the content below

Perianal fistulizing lesions of Crohn’s disease are associated with long-term behavior and its transition: a Chinese cohort study

DOI: https://doi.org/10.5217/ir.2024.00021

XML Download

Figure

Perianal fistulizing lesions of Crohn’s disease are associated with long-term behavior and its transition: a Chinese cohort study

Fig. 1. Alluvial plot of perianal fistulizing lesions with transitional nature of Crohn’s disease (CD). (A) Transition trends of CD behavior. (B) Transition trends of CD location. Transition trends of CD were presented as the flows connecting CD behavior/location from diagnosis to end of follow-up. The flow was colored differently if perianal fistulizing lesions occurred at any time from baseline to the end of followup course (perianal fistulizing lesions=yes). The Montreal classification is as follows: behavior classification (B1, unstructured, non-invasive; B2, structured; B3, infiltrating) and location classification (L1, ileum; L2, colon; L3, ileocolic; L4, isolated upper disease).

Fig. 2. Cumulative percentage of perianal fistulizing lesions after diagnosis of Crohn’s disease (CD). The cumulative percentage of developing perianal fistulizing lesion was 2.7% at 1 year, 7.2% at 5 years, 10.9% at 10 years, and 16.6% at 20 years after diagnosis of CD.

Fig. 3. Comparison of cumulative percentage of perianal fistulizing lesions after diagnosis with different Crohn’s disease (CD) behavior. (A) Comparison at diagnosis. (B) Comparison at follow-up. (C) Comparison according to different transition trends of CD behavior. Classification of CD behavior was categorized as B3 (penetrating) or non-B3 (nonstricturing/nonpenetrating or stricturing) according to the Montreal classification [20]. Note that pairwise log-rank tests for each of the 2 categories of B3 trends indicates significant differences (P<0.001 for non-B3 with progressed to B3, P=0.012 for non-B3 with persistent B3, and P=0.036 for persistent B3 with progressed to B3).

Fig. 1.

Fig. 2.

Fig. 3.

Perianal fistulizing lesions of Crohn’s disease are associated with long-term behavior and its transition: a Chinese cohort study

Characteristic	Perianal lesions, No. (%)	No perianal lesion, No. (%)	P-value
Sex			< 0.001
Male	110 (80.9)	239 (64.9)
Female	26 (19.1)	129 (35.1)
Smoking history			0.740
Never	107 (78.7)	287 (78.0)
Former	16 (11.8)	38 (10.3)
Ongoing	13 (9.6)	43 (11.7)
A classification^a			< 0.001
A1	19 (14.0)	28 (7.6)
A2	98 (72.1)	215 (58.4)
A3	19 (14.0)	125 (34.0)
L classification at diagnosis^a			0.001
L1	26 (19.1)	128 (34.8)
L2	48 (35.3)	84 (22.8)
L3	57 (41.9)	132 (35.9)
L4	5 (3.7)	24 (6.5)
L classification at follow-up^a			< 0.001
L1	11 (8.1)	103 (28.0)
L2	35 (25.7)	57 (15.5)
L3	79 (58.1)	177 (48.1)
L4	11 (8.1)	31 (8.4)
B classification at diagnosis^a			< 0.001
B1	55 (40.4)	176 (47.8)
B2	30 (22.1)	122 (33.2)
B3	51 (37.5)	70 (19.0)
B classification at follow-up^a			< 0.001
B1	24 (17.6)	112 (30.4)
B2	26 (19.1)	135 (36.7)
B3	86 (63.2)	121 (32.9)
Disease activity at diagnosis^b			0.010
Remission	17 (12.5)	59 (16.0)
Mild	30 (22.1)	80 (21.7)
Moderate	53 (39.0)	177 (48.1)
Severe	36 (26.5)	52 (14.1)
Overall extraintestinal manifestation	77 (56.6)	172 (46.7)	0.049
Overall medical therapy
Corticosteroid	110 (80.9)	270 (73.4)	0.082
Immunomodulator	77 (56.6)	203 (55.2)	0.771
Biologic	51 (37.5)	54 (14.7)	< 0.001
Overall severe complications
Obstruction	30 (22.1)	124 (33.7)	0.012
Perforation	46 (33.8)	105 (28.5)	0.250
Massive gastrointestinal bleeding	15 (11.0)	47 (12.8)	0.597
Overall Crohn’s disease-related surgery	36 (26.5)	175 (47.6)	< 0.001

Characteristic	No. of patient (%)
Perianal fistulizing lesions at diagnosis	95 (18.8)
Fistula	68 (13.5)
Abscess	61 (12.1)
Perianal fistulizing lesions at follow-up	136 (27.0)
Fistula	100 (19.8)
Abscess	81 (16.1)
Perianal surgical treatment	104 (20.6)
Drainage seton	17 (3.4)
Fistulotomy	67 (13.3)
Fistulectomy	37 (7.3)
Refractory perianal fistulizing lesions	36 (7.1)

Variable	Hazard ratio (95% CI)	P-value
B3 trends^a		< 0.001
Non-B3	(Ref.)
Progressed to B3	9.90 (4.60–21.33)	< 0.001
Initial B3	4.72 (1.91–11.66)	0.001
CD-related surgery before perianal fistulizing lesions	0.08 (0.03–0.20)	< 0.001
Immunomodulator therapy before perianal fistulizing lesions	0.42 (0.21–0.84)	0.014
Disease activity at diagnosis		0.024
Remission	(Ref.)
Mild	2.11 (0.23–19.19)	0.506
Moderate	6.29 (0.84–47.14)	0.073
Severe	5.59 (0.70–44.47)	0.104
Extraintestinal manifestation	2.03 (1.04–3.93)	0.037

Variable	Odds ratio (95% CI)	P-value
B3 trends^a		0.002
Non-B3	(Ref.)
Progressed to B3	0.16 (0.05–0.54)	0.003
Persistent B3	1.13 (0.41–3.13)	0.817
Disease activity at diagnosis		0.005
Remission	(Ref.)
Mild	8.96 (1.20–66.72)	0.032
Moderate	0.47 (0.12–1.78)	0.266
Severe	1.17 (0.26–5.18)	0.840
L classification at follow-up^b		0.935
L1	(Ref.)
L2	0.84 (0.16–4.58)	0.842
L3	1.16 (0.24–5.65)	0.853
L4^c	-	-

Variable	Odds ratio (95% CI)	P-value
B3 trends^a		0.008
Non-B3	(Ref.)
Progressed to B3	0.91 (0.25–3.26)	0.882
Persistent B3	3.91 (1.36–11.23)	0.011
L classification at follow-up^b		0.061
L1	(Ref.)
L2	0.29 (0.05–1.67)	0.166
L3	0.69 (0.15–3.26)	0.641
L4	2.67 (0.37–19.47)	0.333
Crohn’s disease-related surgery	0.38 (0.13–1.09)	0.072

Table 1. Clinical and Demographical Characteristics of the Cohort Categorized by Perianal Fistulizing Lesions

Patients were categorized by Crohn’s disease-related perianal fistulizing lesions at follow-up.

Subgroups were categorized according to the Montreal classification: age classification (A1, ≤16 yr; A2, 17-40 yr; A3, >40 yr); location classification (L1, ileal; L2, colonic; L3, ileocolonic; L4, isolated upper disease), and behavior classification (B1, non-structuring, non-penetrating; B2, structuring; B3, penetrating). [20]

Subgroups were categorized according to the Harvey-Bradshaw Index. [19]

Table 2. Characteristics of Crohn’s Disease Perianal Fistulizing Lesions

Table 3. Multivariate Cox Regression Model of Perianal Fistulizing Lesions after Diagnosis

B3 refers to penetrating behavior according to the Montreal classification. [20]

CI, confidence interval; Ref., reference level; CD, Crohn’s disease.

Table 4. Multivariate Logistic Regression Model of Fistulotomy/Fistulectomy

B3 refers to penetrating behavior according to the Montreal classification: location classification (L1, ileal; L2, colonic; L3, ileocolonic; L4, isolated upper disease). [20]

Subgroups were categorized according to the Montreal classification. [20]

Estimation of odds ratio for L4 at follow-up deviated because all subjects (n=11) received fistulotomy/fistulectomy.

CI, confidence interval; Ref., reference level.

Table 5. Multivariate Logistic Regression Model of Refractory Perianal Fistulizing Lesions

B3 refers to penetrating behavior according to the Montreal classification. [20]

Subgroups were categorized according to the Montreal classification: location classification (L1, ileal; L2, colonic; L3, ileocolonic; L4, isolated upper disease). [20]